Indeed, FH patients carrying a null‐mutation and therefore with a long‐life exposure to high LDL levels and a severe atherogenic background were those with lower CD163 levels, both in the absence and in the presence of agLDL. The gene discussed is CD163; the disease is familial hyperaldosteronism.